Intraocular Pressure
Conditions
Keywords
Intraocular Pressure (IOP), YM178
Brief summary
The purpose of this study is to assess the affect of mirabegron on intraocular pressure (IOP) in healthy subjects.
Interventions
DRUGMirabegron
oral
DRUGPlacebo
oral
Sponsors
Astellas Pharma Inc
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Female subject must be either post-menopausal (defined as at least 2 years without menses) or surgically sterile (at least 1 month) or of childbearing potential with contraception. All women of childbearing potential will be required to use contraception consisting of two forms of birth control (one of which must be a barrier method), must not be lactating, and must not be breastfeeding during the study period and for 30 days after final study drug administration. All women of childbearing potential must have a negative urine pregnancy test * Male subject with female spouses/partners who are of childbearing potential must use contraception consisting of two forms of birth control (one of which must be a barrier method) during the study period * Subject may either be otherwise healthy or have symptoms of overactive bladder by self-report
Exclusion criteria
* History of glaucoma or ocular hypertension * Abnormal visual field in either eye * Ophthalmic condition that would interfere with reliable Goldmann tonometry (e.g., corneal edema, uveitis, severe keratoconjunctivitis sicca) * History of major ocular infection, inflammation, or herpes simplex keratitis; evidence of current clinically significant blepharitis or conjunctivitis * Any history of ocular surgery including refractive surgery such as laser-assisted in situ keratomileusis (LASIK) or photorefractive keratectomy (PRK) in any eye * Ocular trauma within the past six months * Severe myopia * Diabetes, Type I or Type 2, with or without medical management * Cardiovascular disease requiring pharmacotherapy * History of any type of dysrhythmia * Systemic hypertension requiring pharmacotherapy * Past diagnosis of any connective tissue or autoimmune disease including rheumatoid arthritis and spondyloarthropathies * History of psychiatric illness requiring hospitalization * Recent history (within past 24 months) of alcohol or other substance abuse (with the exception of nicotine) * Used tobacco-containing products or nicotine-containing products within past 3 months * Has been part of any clinical study past within 30 days or currently taking part in a clinical study other than the present study, or has participated in any previous study with mirabegron at any time * Ocular medication of any kind within past 30 days
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline to Day 56 in subject-average intraocular pressure (IOP) | Baseline and Day 56 | Day 56 data will include subjects who discontinue early due to elevated IOP |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline to Day 10 in subject-average IOP | Baseline and Day 10 |
| Number of subjects experiencing increase from baseline in a single-eye IOP by ≥6mmHg in either eye at Day 10 | Baseline and Day 10 |
| Number of subjects experiencing increase from baseline in a single-eye IOP by ≥6mmHg in either eye at Day 56 | Baseline and Day 56 |
| Number of subjects experiencing increase from baseline in a single-eye IOP by≥10 mmHg in either eye at Day 10 | Baseline and Day 10 |
| Number of subjects experiencing increase from baseline in a single-eye IOP by ≥10 mmHg in either eye at Day 56 | Baseline and Day 56 |
Countries
United States
Outcome results
None listed